Dariohealth Corp   (DRIO)
Other Ticker:  
Price: $1.9950 $-0.04 -1.724%
Day's High: $2.0984 Week Perf: -1.24 %
Day's Low: $ 1.99 30 Day Perf: 5.56 %
Volume (M): 46 52 Wk High: $ 5.46
Volume (M$): $ 91 52 Wk Avg: $2.93
Open: $2.07 52 Wk Low: $0.68

 Market Capitalization (Millions $) 57
 Shares Outstanding (Millions) 29
 Employees -
 Revenues (TTM) (Millions $) 25
 Net Income (TTM) (Millions $) 57
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 1

Dariohealth Corp
DarioHealth Corp is a global digital therapeutics company that focuses on providing individuals with chronic conditions access to remote monitoring and management tools. The company offers a mobile platform that allows patients to monitor and manage their health in real-time. Their flagship product, the Dario blood glucose monitoring system, is designed for people with diabetes and enables them to track their blood sugar levels, medication intake, and lifestyle factors.

DarioHealth's platform also includes coaching, education, and support features to empower individuals in self-managing their conditions. By leveraging technology and data analytics, the company aims to improve health outcomes and reduce the burden on healthcare systems. Additionally, DarioHealth offers its digital therapeutics platform to employers and health plans to support their wellness initiatives and lower healthcare costs.

With a user-friendly interface and connectivity to various health devices, DarioHealth provides a convenient and comprehensive solution for individuals with chronic conditions to stay engaged in their healthcare journey. The company operates globally, serving customers in North America, Europe, and Asia-Pacific regions.

   Company Address: 18 W. 18th St. New York 10011 NY
   Company Phone Number: 770-6377   Stock Exchange / Ticker: NASDAQ DRIO
   DRIO is expected to report next financial results on March 08, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Dariohealth Corp

DRIO's Remarkable Decline: A Deep Contraction Spanning July to September 2023

Dariohealth Corp has faced some challenges in the July to September 2023 period, with a decline in income, profits, and revenue compared to the previous year. The company's income fell by -23.44% to $0.49 per share, while profits fell by -15.52% to $0.58 per share. Revenue also took a significant hit, falling by -60.484% to $2.61 million.
This deterioration in the company's top-line is in contrast to the rest of the Medical Equipment & Supplies industry, which experienced a revenue improvement during the same reporting period. However, despite these challenges, Dariohealth Corp is determined to bounce back.

Dariohealth Corp

Despite Impressive Revenue Growth, Dariohealth Corp's Profits Take a Hit in the Second Quarter of 2023: A Concerning Trend for Investors

As an experienced financial journalist, I have closely analyzed the financial results of Dariohealth Corp for the second quarter of 2023. Despite an impressive revenue growth of 19.355% to $6.07 million, the company's profits deteriorated, with income falling by -21.62% to $0.58 per share. This downward trend is concerning for investors and indicates potential challenges that Dariohealth Corp needs to address.
Compared to its industry contemporaries in the Medical Equipment & Supplies sector, Dariohealth Corp has outperformed with its top-line growth. While the industry only expressed a 4.48% revenue growth during the same period, Dariohealth Corp managed to achieve double-digit growth. However, this success in generating revenue did not translate into increased earnings as expected.

Dariohealth Corp

Dariohealth Corp Faces Growing Concerns Over Declining Receivables Turnover Ratio and Collection Challenges in the First Quarter of 2023 Earnings Season

Investors and analysts should take note of the concerning developments in Dariohealth Corp's receivables turnover ratio, indicating difficulties in collecting its outstanding accounts receivable from corporate clients. The ratio has lowered to 6.54, which is below the company average, and a distinct sign of a worsening business environment.
Furthermore, average receivable collection periods for the company saw a decrease to 56 days in the Mar 31 2023 quarter, compared to the preceding quarter, Dec 31 2022, where it stood at 62 days. This phenomenon suggests that the company is finding it increasingly challenging to obtain payments from its clients.
Unfortunately, the situation doesn't seem to be isolated to Dariohealth Corp, as other healthcare companies have higher receivables turnover ratios, indicating overall better performance in terms of collecting payment on outstanding accounts.


Dariohealth's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com